注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
TC BioPharm Ltd是一家临床阶段生物制药公司。该公司致力于开发用于治疗癌症的先进异基因CAR-T细胞治疗产品,以及用于治疗传染病的gamma delta T细胞疗法。它的平台技术允许该公司设计特定疗法,用现成的同种异体gamma delta T细胞(GDT)产品治疗一系列癌症和传染病。该公司的产品线包括OmnImmune、ImmuniStim和CAR-T项目。OmnImmune是一种未经修饰的异基因gamma delta T细胞产品,用于治疗急性髓系白血病(AML)。ImmuniStim是一种未经修饰的异基因 gamma delta T细胞产品,用于治疗新冠肺炎。该公司还在临床前阶段提供内部和合作伙伴项目,重点是开发针对固体和血液学适应症的CAR修饰异基因gamma delta T细胞产品。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Arlene M. Morris | 71 | 2022 | Non-Executive Independent Chair |
Bryan L. Kobel | 42 | 2021 | CEO & Director |
Edward Z. Niemczyk | 43 | 2022 | Non-Executive Independent Director |
James Culverwell | 66 | 2022 | Non-Executive Independent Director |
Isabelle Riviere | - | 2022 | Member of Scientific Advisory Board |
Martin E. Thorp | 71 | 2016 | CFO & Director |
Mark L. Bonyhadi | 70 | 2022 | Chairman of Scientific Advisory Board & Non-Executive Independent Director |
Uma Lakshmipathy | - | 2022 | Member of Scientific Advisory Board |
Daniel Olive | - | 2022 | Member of Scientific Advisory Board |
Blythe Sather | - | 2022 | Member of Scientific Advisory Board |
Erin Adams | - | 2022 | Member of Scientific Advisory Board |
Chris Bond | - | 2022 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核